BioMatrix Flex™
Significant Benefit In Patient-Oriented Outcomes At 3 Years
Significant lower risk in the patient-related composite endpoint of death, MI, and any repeat revascularization at 3 years (Windecker, S., oral presentation, EuroPCR 2011)
Spotlight: LEADERS
LEADERS 4-Year Results Information
The first head-to-head randomized study between the two Drug-Eluting Stent systems (DES) in a ‘real world, all comers’ population using clinical results as a primary endpoints.
Axxess™
Axxess™ - Self-expanding bifurcation DES, is Biosensors’ dedicated bifurcation DES.
The device is the first BA9™-eluting dedicated bifurcation stent, complementing the existing BioMatrix family of product. It features our PLA/BA9™ technology, with an abluminal* biodegradable coating.
* The coating is applied primarily on the abluminal surface.
Live Webcast
Q4 & Full Year FY12 Financial Results Briefing Webcast
Tuesday, 29 May 2012
7pm Singapore local time
1pm CET
6am EST
